Restructuring, Impairment, and Related Charges, Net (Tables)

6 Months Ended

Sep. 30, 2025

Restructuring and Related Activities [Abstract]

Schedule of Restructuring, Impairment, and Related Charges, Net

Restructuring, impairment, and related charges, net for the three months ended September 30, 2025 and 2024 consisted of the following:

	Three Months Ended September 30, 2025
(In millions)	North American Pharmaceutical (1)		Prescription Technology Solutions		Medical-Surgical Solutions (2)		Corporate (3)		Total
Severance and employee-related costs, net	$	4	$	—	$	5	$	—	$	9
Exit and other-related costs (4)	1		—		14		37		52
Asset impairments and accelerated depreciation	1		—		—		1		2
Total	$	6	$	—	$	19	$	38	$	63

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment.

(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.

(3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate activities.

(4)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

	Three Months Ended September 30, 2024
(In millions)	North American Pharmaceutical (1)		Prescription Technology Solutions		Medical-Surgical Solutions (2)		Corporate		Total
Severance and employee-related costs, net	$	1	$	—	$	144	$	4	$	149
Exit and other-related costs (3)	(1)		—		3		10		12
Asset impairments and accelerated depreciation	63		1		—		9		73
Total	$	63	$	1	$	147	$	23	$	234

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations.

(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.

(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Restructuring, impairment, and related charges, net for the six months ended September 30, 2025 and 2024 consisted of the following:

	Six Months Ended September 30, 2025
(In millions)	North American Pharmaceutical (1)		Prescription Technology Solutions		Medical-Surgical Solutions (2)		Corporate (3)		Total
Severance and employee-related costs, net	$	4	$	—	$	10	$	(1)	$	13
Exit and other-related costs (4)	2		—		26		65		93
Asset impairments and accelerated depreciation	1		—		—		3		4
Total	$	7	$	—	$	36	$	67	$	110

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American. Pharmaceutical segment.

(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.

(3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate activities.

(4)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

	Six Months Ended September 30, 2024
(In millions)	North American Pharmaceutical (1)		Prescription Technology Solutions		Medical-Surgical Solutions (2)		Corporate (3)		Total
Severance and employee-related costs, net	$	1	$	—	$	144	$	3	$	148
Exit and other-related costs (3)	(1)		3		6		12		20
Asset impairments and accelerated depreciation	65		2		—		9		76
Total	$	65	$	5	$	150	$	24	$	244

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations.

(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.

(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Schedule of Activity Related to the Liabilities

The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2025:

(In millions)	North American Pharmaceutical		Prescription Technology Solutions		Medical-Surgical Solutions		Corporate		Total
Balance, March 31, 2025 (1)	$	11	$	1	$	90	$	24	$	126
Restructuring, impairment, and related charges, net	7		—		36		67		110
Non-cash charges	(1)		—		—		(3)		(4)
Cash payments	(3)		(1)		(87)		(71)		(162)
Balance, September 30, 2025 (2)	$	14	$	—	$	39	$	17	$	70

(1)As of March 31, 2025, the total reserve balance was $126 million, of which $103 million was recorded within “Other accrued liabilities” and $23 million was recorded within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.

(2)As of September 30, 2025, the total reserve balance was $70 million, of which $52 million was recorded within “Other accrued liabilities” and $18 million was recorded within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.